EGFR and ovarian cancer: CRM197 significantly induced downregulation of EGFR expression (Figure 1A) and activation of JNK/p38MAPK (Figure 1B) in parental (A2780 and SKOV3) and paclitaxel‐resistant (A2780/Taxol and SKOV3/Taxol) ovarian cancer cells (both P < .01), suggesting that CRM197 treatment activates the JNK/p38MAPK pathway by inhibiting EGFR expression.